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Abstract During acute rejection of cardiac transplants
endothelial cell–leukocyte interaction fuelled by co-stimu-
latory molecules like CD40/CD154 may ultimately lead to
graft loss. One key player in up-regulating the expression
of such pro-inﬂammatory gene products is the interferon-
c-dependent transcription factor STAT-1. Hence down-
regulating interferon-c-stimulated pro-inﬂammatory gene
expression in the graft endothelial cells by employing a
decoy oligodeoxynucleotide (dODN) neutralising STAT-1
may protect the graft. To verify this hypothesis, heterotopic
mouse hearttransplantation was performed in the allogeneic
B10.A(2R)toC57BL/6andsyngeneicC57BL/6toC57BL/6
strain combination without immunosuppression. Graft ves-
sels were pre-treated with STAT-1 dODN, mutant control
ODN (10 lM each) or vehicle (Ringer solution). Cellular
rejection (vascular and interstitial component) was graded
histologically and CD40, ICAM-1, VCAM-1, MCP-1,
E-selectin and RANTES expression in the graft monitored
byreal timePCR 24 hand9 dayspost-transplantation.Nine
days after transplantation both rejection scores were signif-
icantly diminished by 85 and 70%, respectively, in STAT-1
dODN-treated allografts as compared to mutant control
ODN-treated allografts. According to immunohistochemis-
try analysis, this was accompanied by a reduced inﬁltration
of monocyte/macrophages and T cells into the graft myo-
cardium.Inaddition,pro-inﬂammatory geneexpression was
strongly impaired by more than 80% in STAT-1 dODN-
treated allografts 24 hpost-transplantation butnotin mutant
control ODN or vehicle-treated allografts. This inhibitory
effect on pro-inﬂammatory gene expression was no longer
detectable 9 days post-transplantation. Single periproce-
dural treatment with a STAT-1 dODN thus effectively
reduces cellular rejection in mouse heart allografts. This
effect is associated both with an early decline in pro-
inﬂammatory gene expression and a later drop in mononu-
clear cell inﬁltration.
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Introduction
Acute cellular rejection jeopardises the short- and long-term
outcomes after heart transplantation. Host immune cells are
recruited from the circulation and directed to the graft by
mechanisms starting with the presentation of allogeneic pep-
tides by antigen-presenting cells to T-helper cells, the
activation of which is further enhanced by co-stimulatory
molecules like CD40/CD154 [4]. As a consequence, the
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molecules on the endothelial cell surface, thus facilitating
monocyte recruitment to the graft and ultimately resulting in
graft damage or failure [4]. One important cytokine produced
by activated T-helper cells is interferon-c (IFN-c). Through
activation of the transcription factor signal transducer and
activator of transcription-1 (STAT-1), IFN-c up-regulates the
expression of a variety of gene products in the donor endo-
thelial cells, which are important for transplant rejection such
as, e.g. CCL5 or RANTES (regulated upon activation, normal
T cell expressed, and secreted), vascular cell adhesion mole-
cule-1(VCAM-1)orCD40[6,9,13,31].Increasedexpression
of VCAM-1 for example enhances endothelial cell–leukocyte
interaction [6], a hallmark of acute cellular rejection.
The role of CD40/CD154 co-stimulation in transplant
rejection has been the subject of extensive research [4, 20],
and histological examination of human cardiac allograft
biopsies has revealed a signiﬁcant correlation between acute
cellular rejection and the increased expression of these mole-
cules on both inﬁltrating leukocytes and microvascular
endothelial cells [25]. Moreover, anti-CD40 monoclonal
antibody treatment in cynomolgus monkeys has been shown
to elicit a potent immunosuppressive effect, thereby pro-
longingallograftsurvival[15].CD40maythusbeconsidered
as a pivotal target molecule in preventing allograft rejection.
Previous in vitro and in vivo experiments have revealed
that STAT-1 is involved in transcriptional regulation of
both the CD40 and VCAM-1 gene which could effectively
be diminished by employing a decoy oligodeoxynucleotide
(dODN) targeting STAT-1 [23, 31]. Decoy ODNs are short
double-stranded DNA molecules that mimic the consensus
binding site of their target transcription factor in the gen-
ome, thereby blocking its activity [21]. Their uptake into
cells is accomplished without the need for a transfection
reagent, most probably through a carrier-based transport
mechanism. By local delivery of an appropriate dODN, the
activities of STAT-1 and STAT-1-dependent gene
expression can be effectively suppressed.
To study the impact of this new therapeutic concept on
graft rejection, we employed an improved STAT-1 dODN
in a heterotopic mouse cardiac transplant model without
immunosuppression. We assessed the effects of a decrease
in STAT-1 activity on vascular and interstitial rejection,
leukocyte inﬁltration and the expression of different pro-
inﬂammatory molecules including CD40 in the graft.
Methods
Animals
Heterotopic heart transplantation was performed in the
B10.A(2R) to C57BL/6 allogeneic mouse model.
Syngeneic C57BL/6 to C57BL/6 transplants served as
controls. All male mice (body weight 25–30 g) were pur-
chased from Charles River (Sulzfeld, Germany) and had
unrestricted access to water and food. They were kept
according to the German legislation on the protection of
animals, and fed standard laboratory chow. The trans-
plantation model used herein consisting of B10.A(2R)
donor (H-2h2; Kk, Db, IAk, IEk) and C57BL/6 acceptor
mice (H-2b, Kb, Db, IAb, IEbetab) is a full MHC mis-
matched strain combination, except for the class I MHC
allele D. In this strain combination with full H-2 histo-
incompatibility, C57BL/6 recipients reject B10.A(2R)
allografts after 10–13 days which is slightly later than in
the BALB/C to C57BL/6 strain combination where donor
hearts are rejected approximately 10 days post-transplan-
tation. To appropriately evaluate the effect of the STAT-1
dODN on acute cellular rejection, it was necessary to
establish an intermediate degree of rejection. Maximal
tissue destruction would perhaps have overridden its pro-
tective effect since no additional immunosuppressive
therapy was employed.
To this end, a pilot study was conducted in which
control allografts were analysed histologically 7, 9 and
12 days after transplantation, respectively (n = 3 each,
data not shown). In addition, beating of the grafts, an
established method to assess graft viability was examined
by daily palpation. After 7 days cellular rejection appeared
to be mild to moderate, after 9 days there was signiﬁcant
damage to the hearts due to acute cellular rejection and
after 12 days grafts were almost fully necrotic. Interest-
ingly, palpation of heart beats revealed palpable pulses in
all grafts. While these were due to myocardial activity 7
and 9 days post-transplantation, the palpable pulses
12 days post-transplantation solely reﬂected atrial but not
ventricular contractions. Therefore, a 9-day follow-up
period was employed in all subsequent experiments to
ensure a good quality histology not affected by autolytic
processes following complete graft failure.
Decoy oligodeoxynucleotide (ODN) technique
Double-stranded ODNs were prepared from complemen-
tary single-stranded phosphorothioate-bonded ODNs
obtained from Eurogentec (Cologne, Germany) by melting
at 95C for 5 min, followed by a cool-down phase of 3–4 h
at ambient temperature. The efﬁciency of the hybridization
reaction was veriﬁed with 2.5% agarose gel electrophoresis
and usually found to exceed 95%. The sequences of the
forward strands were as follows (underlined letters denote
phosphorothioate-bonded bases; mutated bases are printed
in bold and italics).
STAT-1 decoy ODN (dODN): 50-TGTGAATTACCGGA
AGTG-30
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Fluorescent dye-labelled decoy ODN
Consensus STAT-1 dODNs were coupled with ﬂuorescent
Alexa594 (IBA, Go ¨ttingen, Germany) and used at the same
ﬁnal concentration to verify in vivo uptake of the dODN by
the coronary endothelial cells. Analysis was performed on
frozen sections of the mouse hearts. Cells that internalised
the nucleic acid were visualised by ﬂuorescence micro-
scopy with a MicroMax 1300Y CCD camera (Princeton
Instruments, Trenton, NJ, USA) ﬁtted to an Axiovert S100-
TV microscope equipped with a 40x Plan-Neoﬂuar objec-
tive (Carl Zeiss, Jena, Germany). Excitation was performed
with a xenon lamp and a monochromator (TILL-Photonics,
Munich, Germany) set to 580 nm.
Microsurgical technique
Inhalation anaesthesia was performed with isoﬂurane.
Details of the transplantation procedure have been descri-
bed elsewhere [5]. In brief, animals were systemically
heparinised with 50 units of heparin dissolved in 2 ml
Ringer solution intraperitoneally. Hearts were excised after
ligation of the superior and inferior vena cava, the pul-
monary veins and the azygos vein. The ascending aorta was
cut below the brachiocephalic trunk and the pulmonary
artery was cut at the bifurcation of the right and left pul-
monary artery. Then the coronary arteries were perfused
gently by hand either with STAT-1 dODN, mutant control
ODN or Ringer solution only (600 ll each) at room tem-
perature. Hearts were placed in Ringer solution and kept at
4C until implantation (cold ischemia time 10 min).
Implantation of the heart was accomplished by end-to-side
anastomosis of the donor aorta and pulmonary artery to the
infrarenal recipient aorta and infrarenal vena cava,
respectively(warmischemiatime15 min).Awashoutperiod
to prevent any spill over of the ODNs into the systemic cir-
culation followed the completion of the venous anastomosis
before complete declamping. To this end, the distal venous
clampwaspartiallyreleasedtoavoidextensivebloodlossand
a volume of 2–3 heart beats was collected over the venous
anastomosis in a swamp placed directly at the venous anas-
tomosis. The suture was then ﬁnally secured.
Experimental design
To investigate the protective effect of a single (and
selective) pre-treatment of the donor heart endothelium
with the STAT-1 dODN, coronary arteries of allogeneic
transplants were perfused with the naked nucleic acid
dissolved in 600 ll Ringer solution (10 lMﬁ n a lc o n c e n -
tration) over the aortic root (n = 11) directly after
explantation. Hearts perfused with mutant control ODN
served as nucleic acid controls (n = 11). Hearts were
excisedafter 9 days,blotted free from bloodand processed
for standard histology. To assess short-term effects of the
ODNs on mRNA expression of CD40, E-selectin, ICAM-
1, MCP-1, RANTES and VCAM-1 in the allografts, these
were monitored 24 h post-transplantation by real time
PCR (n = 4 for each ODN). In a separate series of
experiments, longitudinal analysis of vascular and inter-
stitial rejection and of changes in pro-inﬂammatory gene
expression after STAT-1 dODN administration to the graft
versus vehicle were analysed histologically, immunohis-
tochemically and by real time PCR 24 h and 9 days post-
t r a n s p l a n t a t i o ni nb o t hs y n g eneic and allogeneic grafts
(n = 3 per group).
Histological evaluation
For histological evaluation, the Banff classiﬁcation for
renal allograft pathology [24] was adopted to the situation
in cardiac allografts according to the score proposed by
Billingham et al. [1]. Light microscopy was performed on
3 lm thin whole heart cross-sections stained with haema-
toxylin and eosin (HE).
Vascular rejection was assessed by an experienced
pathologist blinded towards the treatment regime as fol-
lows: 0 no injury; 0.5 sticking of mononuclear cells to the
endothelium; 1 subendothelial location of mononuclear
cells; 2 inﬂammation of the media, including transmural
inﬁltration (without necrosis); 3 ﬁbrinoid necrosis of the
vessel wall and/or thrombosis of the vessel in addition to
the inﬂammatory reaction. The acute vascular rejection
score was calculated as the sum of all speciﬁc vascular
injury indices, whereby the index of vessels with degree
0.5 was multiplied by 0.5, that of degree 1 by 1, that of
degree 2 by 2 and that of degree 3 by 3, respectively.
Vascular injury was judged in 20 high power ﬁelds
(409 magniﬁcation) of the individual whole heart sections.
Interstitial rejection was evaluated as follows: 1 mild
mononuclear cell inﬁltrate (focal), without myocyte injury;
2 moderately dense inﬁltrate of mononuclear cells, with or
without myocyte injury; 3 diffuse dense monocytic inﬁl-
trate, with or without interstitial oedema, focal interstitial
haemorrhage and/or obvious myocyte injury. It was also
judged in 20 high-power ﬁelds (409 magniﬁcation) of
individual whole heart sections and calculated as described
for the vascular injury score.
Immunohistochemistry analysis
Immunohistochemical staining was performed on 3-lm
sections of zinc ﬁxed tissue, using rat anti-mouse mono-
clonal antibodies against CD3 (T cells in general; BD
Basic Res Cardiol (2009) 104:719–729 721
123Biosciences Pharmingen, San Diego, USA), Ly6 (granulo-
cytes; BD Biosciences Pharmingen) and F4/80 (monocyte/
macrophages;Serotec,Oxford, UK).Interstitialpositive cells
were counted in 10 high-power ﬁelds (409 magniﬁcation) of
individual myocardial sections (left and right ventricle) and
recorded as mean per high-power ﬁeld.
PCR analysis
Real time PCR was performed in a LightCycler (Roche
Diagnostics, Mannheim, Germany). The QuantiTect SYBR
green RT-PCR kit (Qiagen, Hilden, Germany) was used for
real-time quantiﬁcation of target RNA followed by cDNA
synthesis with Sensiscript reverse transcriptase (Qiagen)
and equal amounts of total RNA. Primer sequences used
for PCR ampliﬁcation were: CD40 (GenBank accession
No. X67878, position 488–620, 132 bp fragment, 53C
annealing temperature) 50-TGAGCAACAACTTGGTA
ACCCTGG-30 (sense) and 5-CTGGCTATAAATGGAGC
T-TGACTCG-30 (antisense); VCAM-1 (U12880, 224–288,
64 bp, 60C) 50-CCCCAAGGATCCAGAGATTCA-30
(sense) and 50-ACTTGACCGTGACCGGCTT-30 (anti-
sense); ICAM-1 (X52264, 600–665, 65 bp, 60C)
50-ATCTCAGGCCGCAAGGG-30 (sense) and 50-CGAAAG
TCCGGAGGCTCC-30 (antisense); MCP-1 (NM_011333,
76–139, 63 bp, 60C) 50-TTCCTCCACCACCATGCAG-30
(sense) and 50-CCAGCCGGCAACTGTGA-30 (antisense);
E-selectin (M87862, 1,200–1,336, 136 bp, 55C) 50-AGT
GACACCACAAATCCCAGTCT-30 (sense) and 50-TTCG
CAGGAGAACTCACAACTGGA-30 (antisense); RAN-
TES (NM_013653, 256–412, 157 bp, 62C) 50-GTGC
CAACCCAGAGAAGAAG-30 (sense) and 50-GTAGGGGA
TTACTGGAGTGGC-30 (antisense); GAPDH (BC020308,
563–700, 137 bp, 60C) 50-GACCAC-AGTCCATGCCAT
CACTGC-30 (sense) and 50-ATGACCTTGCCCACAGCC
TTGG-30 (antisense). Fluorescence was monitored (exci-
tation at 470 nm and emission at 530 nm) at the end of the
annealing phase (the LightCycler F1 channel). Except for
RANTES recombinant standards were synthesised in vitro
from the cloned PCR fragments in plasmid DNA (TOPO
TA Cloning kit, Invitrogen). Data derived from the quan-
titative real-time PCR analysis (except for RANTES in
comparison with that of the truncated recombinant stan-
dard) were normalised by using the mRNA level of the
house keeping gene GAPDH as an internal reference and
expressed as the number of copies per ng RNA (copies/ng).
For RANTES the relative expression ratio was calculated
from the real-time PCR efﬁciency and the crossing point
deviation of an unknown sample versus a control as
described by Pfafﬂ [22].
Statistical analysis
Results presented in graphs are expressed as means ±
standard error of the mean (SEM) in each group. Statistical
differences between groups were calculated by using the
non-parametric Mann–Whitney U test with a P value\0.05
considered signiﬁcant.
Results
In vivo up-take of the STAT-1 decoy
oligodeoxynucleotide
Administration of the Alexa594-labelled STAT-1 dODN
under the same conditions as the non-labelled nucleic acid
revealed an almost exclusive uptake by the coronary
endothelial cells of the graft (Fig. 1), conﬁrming them as
the primary target cells of the dODN effect on pro-
inﬂammatory gene expression.
Vascular rejection
Twenty-four hours post-transplantation there was no appre-
ciable cellular rejection in the vasculature of the syngeneic
grafts regardless of the treatment regime (STAT-1 dODN or
vehicle) whereas the allografts revealed a modest increase in
Fig. 1 In vivo uptake of the
Alexa594-labelled STAT-1
dODN (10 lM) by the coronary
endothelial cells of the mouse
heart. Cells that had internalised
the dODN were visualised by
ﬂuorescence microscopy with
emission set to 580 nm. Scale
bar represents 50 lm
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123the vascular injury with no signiﬁcant difference between
STAT-1 dODN application or vehicle at this point (Fig. 2a).
Nine days post-transplantation, isografts also presented
with a modest increase in vascular injury with no signiﬁcant
difference between treatment groups (Fig. 2a). Control allo-
grafts that had received no ODN treatment showed a marked
rise in vascular rejection. This was reduced by about 75% in
allografts that had been treated once with the STAT-1 dODN
at the time of transplantation (Fig. 2a). Histologically, single
treatment of the allograft with the STAT-1 dODN prior to
implantationsigniﬁcantlyreducedleukocyteadherencetothe
graft endothelium, transmural inﬁltration and thrombosis of
capillary vessels when compared to mutant control ODN-
treated hearts (Fig. 3). When compared to the mutant control
ODN group, vascular injury was reduced even further by
approximately 85% in the STAT-1 dODN-treated allografts
(Fig. 2a).
Interstitial rejection
Twenty-four hours post-transplantation there was a modest
increase in interstitial rejection in both isografts and
allografts with no signiﬁcant difference between treatment
groups (Fig. 2b). Nine days post-transplantation the score
had not worsened in the isografts irrespective of the
treatment regime. However, interstitial rejection was
markedly enhanced in the vehicle-treated allografts at this
point, an effect that was prevented by approximately 67%
in STAT-1 dODN-treated allografts (Fig. 2b). Histologi-
cally, there was a signiﬁcant decline in interstitial
leukocyte inﬁltration and damage to the cardiomyocytes in
STAT-1 dODN-treated allografts as compared to mutant
control ODN-treated hearts (Fig. 3). In line therewith,
interstitial injury was also signiﬁcantly reduced by
approximately 64% in the verum group as compared to the
control group (Fig. 2b).
Immunohistochemical quantiﬁcation of the interstitial
inﬁltrate at 24 h and 9 days post-transplantation revealed
no alterations in any of the groups with respect to the
number of granulocytes (Fig. 4a, b). In contrast, there was
a clear-cut rise both in T cell (Fig. 4c, d) and monocyte/
macrophage cell counts (Fig. 4e, f) 9 days post-transplan-
tation in the control allografts but not in the isografts. No
such changes were observed at 24 h. Peri-procedural
application of the STAT1 dODN signiﬁcantly reduced the
number of inﬁltrating T cells in the allografts 9 days post-
transplantation and also had an even more pronounced
effect on the number of monocyte/macrophages which
however did not gain statistical signiﬁcance.
Changes in gene expression
Twenty-four hours post-transplantation CD40mRNAlevels
in whole heart tissue specimens were signiﬁcantly reduced
by approximately 80% in STAT-1 dODN-treated allografts
as compared to mutant control ODN-treated transplants
(Fig. 5a). The same was true for VCAM-1 and MCP-1
expression (Fig. 5b, c). Although reduced to approximately
40% of the level in mutant control ODN-treated transplants,
the STAT-1 dODN effect on ICAM-1 and E-selectin
expression did not gain statistical signiﬁcance (Fig. 5d, e).
In a separate series of experiments, mRNA abundance of
the aforementioned pro-inﬂammatory gene products was
examined in isografts and allografts following STAT-1
dODN or vehicle treatment 24 h and 9 days post-trans-
plantation. At the early point, expression of all gene
products except RANTES (Fig. 6f) was strongly up-regu-
lated in the vehicle-treated allografts as compared to the
respective isograft controls, only E-selectin expression in
the syngeneic controls attained comparatively high levels.
Treatment with the STAT-1 dODN had a profound inhi-
bitory effect on the expression of all gene products (Fig. 6),
the level of which was even lower than in the control
isografts. In contrast, long-term changes in pro-inﬂamma-
tory gene expression were not different between allografts
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(9; n = 14) post-transplantation, respectively (*P\0.05 as indicated)
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123and isografts, irrespective of the treatment regime with two
exceptions. MCP-1 mRNA abundance remained signiﬁ-
cantly elevated in the allografts as compared to the
isografts on day 9 after the transplantation but at one-third
of the expression level in vehicle-treated allografts 24 h
post-transplantation (Fig. 6b). RANTES mRNA abundance
on the other hand was markedly increased in the control
allografts on day 9 as compared to 24 h after the trans-
plantation (Fig. 6b), compatible with its role as a late-
reacting cytokine. Note that even though Figs. 5 and 6
display essentially the same data for the 24-h period these
are derived from different sets of experiments so that the
absolute copy numbers cannot be lumped together.
Discussion
Despite new pharmacological therapies and the introduc-
tion of ventricular assist devices, heart transplantation
remains the gold standard in the therapy of end-stage
heart failure in selected patients [7, 8]. Irrespective of the
availability of powerful immunosuppressants, acute rejec-
tion episodes continue to pose a major problem in heart
transplantation.
During acute rejection, recipient T cell activation fuelled
by graft co-stimulatory molecules such as CD40/CD154 up-
regulates expression of IFN-c [6, 32], interleukins 1, 6, 8
and 12 as well as TNF-a and MIP-1a in dendritic cells [3]
and that of E-selectin, VCAM-1 and ICAM-1 in the endo-
thelial cells of the graft blood vessels [16]. Furthermore,
MCP-1/CCL2 and RANTES/CCL5, potent chemotactic
factors for monocytes, CD4
? and CD8
? positive T cells,
basophils, and eosinophils [26] have been shown, albeit
with different kinetics, to be up-regulated in cardiac allo-
grafts [9, 13, 27], an effect that may also have important
consequences for chronic graft rejection, i.e. transplant
arteriosclerosis [33]. As a result, recruitment and invasion
of mononuclear cells, namely monocytes and T cells, into
the transplant is augmented with the ensuing acute inﬂam-
matory response presumably leading to graft loss.
In the present series of experiments, we targeted CD40/
CD154-mediated endothelial cell/T-helper cell co-stimu-
lation by employing an optimised dODN that neutralises
the transcription factor STAT-1 and thus down-regulates
expression of most IFN-c-dependent pro-inﬂammatory
genes including CD40. To prove that the graft endothelial
cells are in fact the primary target cells of the dODN, a
ﬂuorescence dye-labelled ODN was administered intra-
luminally in the same way as the non-labelled nucleic acid
and revealed that the endothelial cells of the donor heart in
fact take up the bulk of the labelled dODN. It is likely,
therefore, that this route of application restricts the effects
of the dODN on gene expression to the graft endothelium.
Single application of the STAT-1 dODN but not that of
a mutant control ODN to coronary vessels of the donor
heart prior to implantation resulted in a pronounced down-
Fig. 3 Representative
histological sections 9 days
post-transplantation in mutant
control ODN-treated allografts
(STAT-1 mut) and STAT-1-
dODN-treated allografts
(STAT-1). Allografts treated
with the mutant control ODN
showed a dense inﬁltrate with
mononuclear cells and a
scattered, loosened appearance
of the myocardium (a, b). In
contrast, myocardial
architecture was still preserved
with a much reduced inﬁltrate of
mononuclear cells in STAT-1
dODN-treated allografts (c, d).
Scale bar represents 100 lmi n
a and c, and 50 lmi nb and d
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123regulation not only of CD40 but also of E-selectin,
ICAM-1, MCP-1, RANTES and VCAM-1 expression in
the allografts 24 h post-transplantation. The level of
expression of these pro-inﬂammatory gene products at this
point following STAT1 dODN treatment was much lower
yet than in control isografts which irrespective of the
treatment regime did not reveal this early change in pro-
inﬂammatory gene expression. Only E-selectin mRNA
levels appeared to be elevated about threefold in control
isografts at 24 h as compared to 9 days post-transplanta-
tion, indicative of a modest surgical or ischemia/
reperfusion injury-induced trauma. Expression of the
aforementioned gene products in the allograft most likely
is IFN-c-dependent and governed by activation of the
transcription factor STAT-1 [2, 6, 31]. Moreover, some of
these pro-inﬂammatory gene products as, e.g. MCP-1
have been shown to up-regulate the expression of addi-
tional pro-inﬂammatory gene products [28]s ot h a tS T A T - 1
dODN blockade of IFN-c-induced MCP-1 expression may
have affected a much broader pattern of pro-inﬂammatory
genes. In this context, it should also be emphasised that the
dODN employed most likely binds with similar afﬁnity to
STAT-1 and STAT-3 [14]. It cannot be excluded, therefore,
that down-regulation of STAT-3-dependent genes may have
contributed to the potent anti-inﬂammatory effect of the
STAT1 dODN in our mouse cardiac allograft model.
Apart from MCP-1 (and possibly RANTES) mRNA
abundance which was still signiﬁcantly up-regulated
in the allografts as compared to the isografts 9 days
post-transplantation, there were no long-term changes in
pro-inﬂammatory gene expression in the donor hearts.
Moreover, STAT-1 dODN inhibition of pro-inﬂammatory
gene expression was no longer evident at this point. The
most likely reason for this apparent lack of effect is the
relative instability of the nucleic acid in the target tissue
over such a long period (cf. [12]). Nonetheless, its effect on
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Fig. 4 Immunohistochemical
analysis of myocardial
inﬁltration by granulocytes
(Ly6), T cells (CD3) or
monocyte/macrophages (F4/80)
in allografts (allo) or isografts
(iso) pre-treated with the STAT-
1 dODN (STAT) or vehicle
(cont) 24 h and 9 days post-
transplantation, respectively
(n = 3, *P\0.05 as indicated)
Basic Res Cardiol (2009) 104:719–729 725
123early changes in gene expression had a profound inﬂuence
on the histological appearance of the allografts. Thus, there
was a signiﬁcant and robust reduction both in vascular and
interstitial rejection. In contrast, there were no appreciable
changes in the histological appearance of the isografts at
this point, irrespective of the treatment regime. This ﬁnding
is in line also with the immunohistochemical quantiﬁcation
of the number of inﬁltrating leukocytes in the graft myo-
cardium which was essentially unaltered in the isografts at
any time. No increase in leukocyte cell counts was likewise
noted in the allografts 24 h post-transplantation whereas
both monocyte/macrophage and especially T cell numbers
were clearly up-regulated at the end of the 9-day follow-up
period. Periprocedural administration of the STAT-1
dODN reduced the inﬁltration of both cell types at this
point underlining not only its inhibitory effect on cellular
rejection per se but also that early rather than late changes
in pro-inﬂammatory gene expression are decisive for this to
occur.
Anoteofcautionmaybeappropriatethoughwithregardto
the possibility of a dissociation between pro-inﬂammatory
gene expression and mononuclear cell inﬁltration in the
courseofrejection.Evenifup-regulationofpro-inﬂammatory
gene expression in the allograft 24 h post-transplantation is
Fig. 5 Real time PCR analysis
of CD40, E-selectin, ICAM-1,
MCP-1 and VCAM-1 mRNA
abundance in the allografts
treated with the STAT-1 dODN
(STAT) or the mutant control
ODN (STAT mut) 24 h post-
transplantation (n = 4,
*P\0.05 vs. mutant control
ODN)
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123observedratherfrequently[12,29],thisdoesnotmeanthatthe
maximum level ofexpressionisalready attained atthispoint.
Ontheotherhand,maximuminﬁltrationofmononuclearcells
intotheallografttypicallyoccursseveraldayslater[12,30]so
thattemporallybothparametersseemtobeclearlysegregated.
Moreover, the possibility that the early rise in pro-inﬂamma-
torygeneexpressioninthe cardiac allografts isattributable in
part to perioperative ischemic injury triggering an innate
response rather than a graft-speciﬁc alloresponse cannot be
disregarded.
Theﬁndingthat periproceduralSTAT-1 dODN treatment
inhibited pro-inﬂammatory gene expression in the cardiac
allografts 24 h but not 9 days post-transplantation likewise
must not support the aforementioned hypothesis of a
Fig. 6 Real time PCR analysis of CD40, E-selectin, MCP-1,
ICAM-1, RANTES and VCAM-1 mRNA abundance in allografts
(allo) or isografts (iso) pre-treated with the STAT-1 dODN (STAT)
or vehicle (cont) 24 h and 9 days post-transplantation, respectively
(n = 3, *P\0.05 as indicated)
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123temporal division between pro-inﬂammatory gene expres-
sion and mononuclear cell inﬁltration in the course of
rejection. Temporally similar effects on pro-inﬂammatory
gene expression (near maximum inhibition at 24 h, modest
inhibition at 3 days post-transplantation) have previously
been observed with the STAT-1 dODN in a rat cardiac
allograft model [12], suggesting that its duration of action is
associated with its intracellular stability rather than the
underlyingpathogeneticmechanism.Infact,fromallanimal
experimental in vivomodels with single application of these
nucleicacidsconductedthusfararapidonsetwithanaverage
duration of action of up to 3 or 4 days may be inferred.
However, to avoid any uncertainty in correctly interpreting
the present data it would have been desirable to include an
additional 3–5-day time point in our mouse cardiac trans-
plant model. Regrettably, this was precluded by the limited
availability of the B10.A(2R) donor mice.
Notwithstandingthisthe aforementionedﬁndingsmay be
interpreted as follows: (1) STAT-1 dODN treatment atten-
uates the immune response of the host against the graft, (2)
IFN-c-mediated up-regulation of pro-inﬂammatory gene
expression including but not exclusive to that of CD40
preferentially in the donor endothelium plays a major role in
exacerbating the cellular rejection process. These conclu-
sions are supported by previous ﬁndings with anti-CD154
antibodies that prolong allograft survival both in rodent and
primate transplantation models [10, 11, 18, 32] and, more
recently, with anti-CD40 antibodies that prolong kidney
allograft survival in monkeys [15]. However, despite these
promising pre-clinical data, clinical application of the anti-
CD154antibodieshasbeenwroughtwithdifﬁcultyprimarily
due to serious thromboembolic complications [17, 19].
In conclusion, the aforementioned ﬁndings establish a
novel therapeutic principle to reduce acute and possibly also
chronicgraftrejection[29].Byneutralisingthetranscription
factor STAT-1, decoy ODNs exert a powerful long-lasting
anti-inﬂammatory effect. These nucleic acid-based drugs
offer the advantage of a rapid uptake by their target cells;
here the endothelial cells lining the coronary arteries of the
donor heart, without any transfection reagent. They may
therefore represent a novel periprocedural therapeutic per-
spective for the adjunct protection (in combination with
standard immunosuppressants) of difﬁcult transplants such
as the heart.
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